C12N2501/2304

B-CELL CULTIVATION METHOD
20240002794 · 2024-01-04 · ·

Herein is reported a method for co-cultivating one or more B-cells comprising the step of incubating the one or more B-cells with EL4-B5 cells, whereby the EL4-B5 cells have been obtained/are from a cultivation of EL4-B5 cells that has a cell density of from 600,000 cells/ml up to 1,500,000 cells/ml.

Dendritic cell composition

The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.

B-CELL CULTIVATION METHOD
20200399596 · 2020-12-24 · ·

Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.

APPLICATIONS OF SOLUBLE PROTEIN BAFF IN B CELL IN-VITRO CULTURE AND PROLIFERATION
20200362014 · 2020-11-19 ·

Disclosed in the present invention is an application of soluble protein BAFF in B cell in-vitro culture and proliferation. Peptide expressed by secretory BAFF peptide in the present invention can be effectively secreted out of cells to generate corresponding bioactivity. During the process of culture, a cell line in the present invention can continuously secrete water-soluble BAFF protein having bioactivity, the water-soluble BAFF protein served as tool cells are co-cultured with B cells, and in-vitro proliferation and antigen presentation effects of human B cells can be effectively improved.

METHOD FOR EXPANSION OF LYMPHOCYTES

The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).

METHODS OF MANUFACTURING ALLOGENEIC CAR T CELLS

Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).

METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPY

Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

METHOD FOR PREPARING ANTIGEN-SPECIFIC REGULATORY T CELLS

Provided is a method for producing regulatory T cells for inducing immune tolerance in a subject. The method comprises the step of co-culturing regulatory T cells obtained from the subject with dendritic cells derived from iPS cells.

Method for producing B cell population

It is an object of the present invention to provide a method for easily producing an antigen-specific B cell population comprising IgG-positive B cells specific to a specific antigen. The present invention provides a method for producing a B cell population, comprising culturing B cells, in which the expression of a Bach2 gene has been increased, in the presence of a means for acting on CD40 and/or a BAFF receptor.

METHOD FOR ACTIVATING T CELLS FOR CANCER TREATMENT
20200289630 · 2020-09-17 ·

The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 214, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.